Over the past decade, pharmacogenetic testing has emerged in clinical practice to guide
selected cardiovascular therapies. The most common implementation in practice is …

The goal of the Association for Molecular Pathology (AMP) Clinical Practice Committee's
AMP Pharmacogenomics (PGx) Working Group is to define the key attributes of PGx alleles …

Response to medications, the principal treatment modality for acute and chronic diseases, is
highly variable, with 40–70% of patients exhibiting lack of efficacy or adverse drug reactions …

Mitochondrial Cardiomyopathy (MCM) is a common manifestation of multi-organ
Mitochondrial Diseases (MDs), occasionally present in non-syndromic cases. Diagnosis of …

ABSTRACT Introduction Neuropsychiatric disorders (NPDs)(neurodevelopmental, mental,
neurodegenerative, neurotoxic, complex disorders) are the third major problem of health in …

Background Several studies optimized the warfarin dose based on CYP2C9* 2, CYP2C9* 3,
VKORC1-1639 G> A, CYP4F2 V433M. But, the information on the rare variants is lacking. In …

There is a special interest in the implementation of pharmacogenetics in clinical practice,
although there are some barriers that are preventing this integration. A large part of these …

Patients with venous thromboembolism (VTE) require immediate treatment with
anticoagulants such as acenocoumarol. This multicentre randomised clinical trial evaluated …

Cytochrome P450 4F2 (CYP4F2) is an enzyme that is involved in the metabolism of
arachidonic acid (AA), vitamin E and K, and xenobiotics including drugs. CYP4F2* 3 …

Introduction Warfarin's narrow therapeutic index and high variability in dosage requirements
make dosage selection critical. Genetic factors are known to impact warfarin dosage …